Responses
Regular and young investigator award abstracts
Clinical trials in progress
313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms
Compose a Response to This Article
Other responses
No responses have been published for this article.